To: The Copenhagen Stock Exchange

TRANSLATION

Announcement No. 1 in 2007
January 3, 2007

ALK-Abelló and Schering-Plough enter strategic alliance

Summary: *ALK-Abelló and Schering-Plough have signed an agreement on a strategic alliance to develop and commercialize ALK-Abelló's tablet-based immunotherapies against grass pollen allergy (GRAZAX®), house dust mite allergy and ragweed allergy for the North American market.*

ALK-Abelló and Schering-Plough (NYSE: SGP) have signed an agreement on a strategic alliance to develop and commercialize ALK-Abelló's tablet-based immunotherapy in the USA, Canada and Mexico. The agreement gives Schering-Plough exclusive license rights to develop, market and distribute the tablet-based immunotherapies against grass pollen allergy (GRAZAX®), house dust mite allergy and ragweed allergy.

Under the agreement, ALK-Abelló will receive an up-front payment of USD 35 million (approximately DKK 200 million) from Schering-Plough. In addition, ALK-Abelló may receive up to a total of USD 255 million (approximately DKK 1,430 million) of milestone payments. Out of this amount, USD 65 million (approximately DKK 370 million) relates to the clinical development and regulatory events for the three tablet-based immuno-therapies and the rest to the achievement of specific milestones related to realized sales of the tablets. In addition, ALK-Abelló will be entitled to royalty payments on net sales of the products on the North American market. Schering-Plough will be responsible for all costs of clinical development, registration, marketing and sales of the products on the North American market. ALK-Abelló will be responsible for tablet production and supply.

The agreement is subject to approval by the Federal Trade Commission in the USA.

Hørsholm, January 3, 2007
ALK-Abelló A/S

Jens Bager
President and CEO

ALK-Abelló holds a conference call for analysts and investors today at 3.30 p.m. (CET) at which Jens Bager will review the agreement and answer questions. Danish participants must call in on tel +45 7026 5040 before 3.25 p.m. (CET), and international participants must call in on tel +44 207 769 6432 before 3.25 p.m. (CET). A short presentation will be available on the company's website prior to the meeting.

For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7445

ALK-ABELLÓ A/S • BØGE ALLÉ 6-8 • P.O. BOX 408 • DK-2970 HØRSHOLM • DENMARK • WWW.ALK-ABELLO.COM
TEL +45 4574 7445 • FAX +45 4574 8607 • CVR NO. 63 71 79 16

About ALK-Abelló

ALK-Abelló is devoted to improving the lives of people with allergies by developing pharmaceutical products that target the cause of their allergic disease. ALK-Abelló is the world leader in the development of immunotherapy treatments – a unique treatment that induces a protective immune response with sustained symptom prevention. Allergy immunotherapy is traditionally conducted as subcutaneous injections or sublingual droplets. ALK-Abelló aims to extend the use of immunotherapy by introducing convenient tablets for home treatment, thereby offering many more patients a causal allergy treatment. ALK-Abelló has more than 1,300 employees with subsidiaries, production facilities and distributors throughout the world. The company is headquartered in Hørsholm, Denmark and listed on the Copenhagen Stock Exchange (ticker symbol ALK B).

Read more on www.alk-abello.com

ALK-ABELLÓ A/S • BØGE ALLÉ 6-8 • P.O. BOX 408 • DK-2970 HØRSHOLM • DENMARK • WWW.ALK-ABELLO.COM
TEL +45 4574 7445 • FAX +45 4574 8607 • CVR NO. 63 71 79 16